Octreotide, 30 mg i.m. LAR formulation

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Proliferative Diabetic Retinopathy

Conditions

Proliferative Diabetic Retinopathy

Trial Timeline

Dec 1, 2003 → —

NCT ID

NCT00170742

About Octreotide, 30 mg i.m. LAR formulation

Octreotide, 30 mg i.m. LAR formulation is a phase 3 stage product being developed by Novartis for Proliferative Diabetic Retinopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00170742. Target conditions include Proliferative Diabetic Retinopathy.

What happened to similar drugs?

3 of 9 similar drugs in Proliferative Diabetic Retinopathy were approved

Approved (3) Terminated (1) Active (5)

🔄Brolucizumab 6 mgNovartisPhase 3

✅LucentisNovartisApproved

✅RanibizumabNovartisApproved

✅Macugen ® (pegaptanib sodium)PfizerApproved

🔄Intravitreal aflibercept injection [IAI] + ShamRegeneron PharmaceuticalsPhase 3

🔄Ruxolitinib + PlaceboIncytePhase 3

🔄Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24Ocular TherapeutixPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00170742	Phase 3	Terminated	Dec 1, 2003	—	Proliferative Diabetic Retinopathy

Competing Products

20 competing products in Proliferative Diabetic Retinopathy

See all competitors

Product	Company	Stage	Hype Score
LY2784544	Eli Lilly	Phase 1	29
LY2784544	Eli Lilly	Phase 1	29
Navitoclax + Ruxolitinib + Celecoxib	AbbVie	Phase 1	33
Epcoritamab	AbbVie	Phase 1	36
Brolucizumab 6 mg	Novartis	Phase 3	40
CANAKINUMAB (ILARIS®)	Novartis	Phase 1	21
Lucentis	Novartis	Approved	43
Ranibizumab	Novartis	Approved	39
Ranibizumab 0.5 mg	Novartis	Phase 2	35
AUY922	Novartis	Phase 2	27
Lucentis	Roche	Pre-clinical	22
Macugen (pegaptanib) + Macugen (Pegaptanib)	Pfizer	Pre-clinical	26
Macugen ® (pegaptanib sodium)	Pfizer	Approved	39
Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine	Swedish Orphan Biovitrum	Phase 2	42
Fedratinib Pill	Bristol Myers Squibb	Phase 2	39
VAC85135 + Ipilimumab	Bristol Myers Squibb	Phase 1	29
Fedratinib Pill	Bristol Myers Squibb	Phase 1	21
Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg	Bristol Myers Squibb	Phase 1	21
Aflibercept	Regeneron Pharmaceuticals	Phase 2	35
2-mg Intravitreous Aflibercept Injection	Regeneron Pharmaceuticals	Phase 2/3	38